[1] |
MCCARRON R M, SHAPIRO B, RAWLES J, et al. Depression [J]. Ann Intern Med, 2021, 174(5): ITC65-ITC80.
|
[2] |
MONROE S M, HARKNESS K L. Major Depression and Its Recurrences: Life Course Matters [J]. Annu Rev Clin Psychol, 2022, 18: 329-357. doi:10.1146/annurev-clinpsy-072220-021440
doi: 10.1146/annurev-clinpsy-072220-021440
|
[3] |
ZHAO J L, JIANG W T, WANG X, et al. Exercise, brain plasticity, and depression [J]. CNS Neurosci Ther, 2020, 26(9): 885-895. doi:10.1111/cns.13385
doi: 10.1111/cns.13385
|
[4] |
WANG X, LI S, YU J, et al. Saikosaponin B2 ameliorates depression-induced microglia activation by inhibiting ferroptosis-mediated neuroinflammation and ER stress [J]. J Ethnopharmacol, 2023, 316: 116729. doi:10.1016/j.jep.2023.116729
doi: 10.1016/j.jep.2023.116729
|
[5] |
何俊荣, 刘仔, 陈锡培. 布洛芬对缺血性脑中风大鼠的神经保护作用及对Nrf2/SLC7A11/GPX4信号通路的影响 [J]. 实用医学杂志, 2023, 39(15): 1888-1892.
|
[6] |
ALMULLA A F, THIPAKORN Y, ALGON A A A, et al. Reverse cholesterol transport and lipid peroxidation biomarkers in major depression and bipolar disorder: A systematic review and meta-analysis [J]. Brain Behav Immun, 2023, 113: 374-388. doi:10.1016/j.bbi.2023.08.007
doi: 10.1016/j.bbi.2023.08.007
|
[7] |
KUWAKI T. Orexin/hypocretin [J]. Peptides, 2024, 173: 171153. doi:10.1016/j.peptides.2024.171153
doi: 10.1016/j.peptides.2024.171153
|
[8] |
TOOR B, RAY L B, POZZOBON A, et al. Sleep, Orexin and Cognition [J]. Front Neurol Neurosci, 2021, 45: 38-51. doi:10.1159/000514960
doi: 10.1159/000514960
|
[9] |
MAVANJI V, POMONIS B, KOTZ C M. Orexin, serotonin, and energy balance [J]. WIREs Mech Dis, 2022, 14(1): e1536. doi:10.1002/wsbm.1536
doi: 10.1002/wsbm.1536
|
[10] |
KISHI T, KOEBIS M, SUGAWARA M, et al. Orexin receptor antagonists in the treatment of insomnia associated with psychiatric disorders: A systematic review [J]. Transl Psychiatry, 2024, 14(1): 374. doi:10.1038/s41398-024-03087-4
doi: 10.1038/s41398-024-03087-4
|
[11] |
蒋召书, 程茗, 杨洁, 等. 食欲素及其受体相关药物对抑郁症影响的研究进展 [J]. 中国药房, 2025, 36(4): 496-500.
|
[12] |
张震, 赵博, 刘炽鉴, 等. 柴胡疏肝散对CUMS大鼠眶额叶皮层的保护作用机制 [J]. 中药材, 2021, 44(7): 1713-1718. doi:10.13863/j.issn1001-4454.2021.07.031
doi: 10.13863/j.issn1001-4454.2021.07.031
|
[13] |
YAN H F, ZOU T, TUO Q Z, et al. Ferroptosis: Mechanisms and links with diseases [J]. Signal Transduct Target Ther, 2021, 6(1): 49. doi:10.1038/s41392-020-00428-9
doi: 10.1038/s41392-020-00428-9
|
[14] |
REICHERT C O, DE FREITAS F A, SAMPAIO-SILVA J, et al. Ferroptosis Mechanisms Involved in Neurodegenerative Diseases [J]. Int J Mol Sci, 2020, 21(22):8765. doi:10.3390/ijms21228765
doi: 10.3390/ijms21228765
|
[15] |
WANG Y L, WU H R, ZHANG S S, et al. Catalpol ameliorates depressive-like behaviors in CUMS mice via oxidative stress-mediated NLRP3 inflammasome and neuroinflammation [J]. Transl Psychiatry, 2021, 11(1): 353. doi:10.1038/s41398-021-01468-7
doi: 10.1038/s41398-021-01468-7
|
[16] |
CHEN Y, ZHANG Y, WANG J, et al. Anti-neuroinflammation effects of transcutaneous auricular vagus nerve stimulation against depression-like behaviors via hypothalamic α7nAchR/JAK2/STAT3/NF-κB pathway in rats exposed to chronic unpredictable mild stress [J]. CNS Neurosci Ther, 2023, 29(9): 2634-2644. doi:10.1111/cns.14207
doi: 10.1111/cns.14207
|
[17] |
CHEN B, JIN K, DONG J, et al. Hypocretin‐1/Hypocretin Receptor 1 Regulates Neuroplasticity and Cognitive Function through Hippocampal Lactate Homeostasis in Depressed Model [J]. Adv Sci (Weinh),2024, 11(38): e2405354. doi:10.1002/advs.202405354
doi: 10.1002/advs.202405354
|
[18] |
HILL S A, BLAESER A S, COLEY A A, et al. Sonic hedgehog signaling in astrocytes mediates cell type-specific synaptic organization [J]. Elife, 2019, 8:e45545. doi:10.7554/elife.45545
doi: 10.7554/elife.45545
|
[19] |
MOHAMMADKHANI A, MITCHELL C, JAMES M H, et al. Contribution of hypothalamic orexin (hypocretin) circuits to pathologies of motivation [J]. Br J Pharmacol, 2024, 181(22): 4430-4449. doi:10.1111/bph.17325
doi: 10.1111/bph.17325
|
[20] |
LI H, LU J, LI S, et al. Increased Hypocretin (Orexin) Plasma Level in Depression, Bipolar Disorder Patients [J]. Front Psychiatry, 2021, 12: 676336. doi:10.3389/fpsyt.2021.676336
doi: 10.3389/fpsyt.2021.676336
|
[21] |
LIN C C, HUANG T L. Orexin/hypocretin and major psychiatric disorders [J]. Adv Clin Chem, 2022, 109: 185-212. doi:10.1016/bs.acc.2022.03.006
doi: 10.1016/bs.acc.2022.03.006
|
[22] |
CHEN B, JIN K, DONG J, et al. Hypocretin-1/Hypocretin Receptor 1 Regulates Neuroplasticity and Cognitive Function through Hippocampal Lactate Homeostasis in Depressed Model [J]. Adv Sci (Weinh), 2024, 11(38): e2405354. doi:10.1002/advs.202405354
doi: 10.1002/advs.202405354
|
[23] |
ZHANG R, LI D, MAO H, et al. Disruption of 5-hydroxytryptamine 1A receptor and orexin receptor 1 heterodimer formation affects novel G protein-dependent signaling pathways and has antidepressant effects in vivo [J]. Transl Psychiatry, 2022, 12(1): 122. doi:10.1038/s41398-022-01886-1
doi: 10.1038/s41398-022-01886-1
|
[24] |
SONG Y, LI J, LI H, et al. The role of ventral tegmental area orexinergic afferents in depressive-like behavior in a chronic unpredictable mild stress (CUMS) mouse model [J]. Biochem Biophys Res Commun, 2021, 579: 22-28. doi:10.1016/j.bbrc.2021.09.062
doi: 10.1016/j.bbrc.2021.09.062
|
[25] |
HAN S, LI X X, WEI S, et al. Orbitofrontal cortex-hippocampus potentiation mediates relief for depression: A randomized double-blind trial and TMS-EEG study [J]. Cell Rep Med, 2023, 4(6): 101060. doi:10.1016/j.xcrm.2023.101060
doi: 10.1016/j.xcrm.2023.101060
|
[26] |
ZHANG B, ROLLS E T, WANG X, et al. Roles of the medial and lateral orbitofrontal cortex in major depression and its treatment [J]. Mol Psychiatry, 2024, 29(4): 914-928. doi:10.1038/s41380-023-02380-w
doi: 10.1038/s41380-023-02380-w
|
[27] |
XU Y, JIA B, LI J, et al. The Interplay between Ferroptosis and Neuroinflammation in Central Neurological Disorders [J]. Antioxidants (Basel), 2024, 13(4):395. doi:10.3390/antiox13040395
doi: 10.3390/antiox13040395
|
[28] |
ZHANG G, LV S, ZHONG X, et al. Ferroptosis: A new antidepressant pharmacological mechanism [J]. Front Pharmacol, 2023, 14: 1339057. doi:10.3389/fphar.2023.1339057
doi: 10.3389/fphar.2023.1339057
|
[29] |
DANG R, WANG M, LI X, et al. Edaravone ameliorates depressive and anxiety-like behaviors via Sirt1/Nrf2/HO-1/Gpx4 pathway [J]. J Neuroinflammation, 2022, 19(1): 41. doi:10.1186/s12974-022-02400-6
doi: 10.1186/s12974-022-02400-6
|
[30] |
LI E, YIN H, SU M, et al. Inhibition of ferroptosis alleviates chronic unpredictable mild stress-induced depression in mice via tsRNA-3029b [J]. Brain Res Bull, 2023, 204: 110773. doi:10.1016/j.brainresbull.2023.110773
doi: 10.1016/j.brainresbull.2023.110773
|
[31] |
FENG X, ZHANG W, LIU X, et al. Ferroptosis-associated signaling pathways and therapeutic approaches in depression [J]. Front Neurosci, 2025, 19: 1559597. doi:10.3389/fnins.2025.1559597
doi: 10.3389/fnins.2025.1559597
|
[32] |
SOWA-KUĆMA M, STYCZEŃ K, SIWEK M, et al. Lipid Peroxidation and Immune Biomarkers Are Associated with Major Depression and Its Phenotypes, Including Treatment-Resistant Depression and Melancholia [J]. Neurotox Res, 2018, 33(2): 448-460. doi:10.1007/s12640-017-9835-5
doi: 10.1007/s12640-017-9835-5
|
[33] |
CAI M Y, YANG Z, HUANG X J, et al. Mongolian Medicine Areca Thirteen Pill (GY-13) Improved Depressive Syndrome via upregulating cAMP/PKA/CREB/BDNF signaling pathway [J]. J Ethnopharmacol, 2022, 293: 115310. doi:10.1016/j.jep.2022.115310
doi: 10.1016/j.jep.2022.115310
|
[34] |
CHANG B, LIU Y, HU J, et al. Bupleurum chinense DC improves CUMS-induced depressive symptoms in rats through upregulation of the cAMP/PKA/CREB signalling pathway [J]. J Ethnopharmacol, 2022, 289: 115034. doi:10.1016/j.jep.2022.115034
doi: 10.1016/j.jep.2022.115034
|
[35] |
ABOUNOORI M, MADDAH M M, ARDESHIRI M R. Orexin neuropeptides modulate the hippocampal-dependent memory through basolateral amygdala interconnections [J]. Cereb Circ Cogn Behav, 2022, 3: 100035. doi:10.1016/j.cccb.2021.100035
doi: 10.1016/j.cccb.2021.100035
|
[36] |
ZHOU A, FENG H Y, FAN C N, et al. Asiaticoside Attenuates Chronic Restraint Stress-Induced Hippocampal CA1 Neuronal Ferroptosis via Activating BDNF/Nrf2/GPX4 Signaling Pathway [J]. Drug Des Devel Ther, 2025, 19: 793-810. doi:10.2147/dddt.s509208
doi: 10.2147/dddt.s509208
|